EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nascent Pharma Holdings's Enterprise Value is $18.15 Mil.
Nascent Pharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $0.25 Mil. Therefore, Nascent Pharma Holdings's EV-to-FCF for today is 73.80.
The historical rank and industry rank for Nascent Pharma Holdings's EV-to-FCF or its related term are showing as below:
NASC'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 75.23
Current: 73.8
During the past 13 years, the highest EV-to-FCF of Nascent Pharma Holdings was 75.23. The lowest was 0.00. And the median was 0.00.
NASC's EV-to-FCF is not ranked
in the Drug Manufacturers industry.
Industry Median: 20.02
vs NASC: 73.80
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nascent Pharma Holdings's PE Ratio (TTM) for today is calculated as:
Nascent Pharma Holdings's share price for today is $0.0103.
Nascent Pharma Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.305.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nascent Pharma Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nascent Pharma Holdings EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nascent Pharma Holdings's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nascent Pharma Holdings's EV-to-FCF falls into.
Nascent Pharma Holdings's current Enterprise Value is $18.15 Mil.
Nascent Pharma Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nascent Pharma Holdings (NASC) has a EV-to-FCF of 73.80 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nascent Pharma Holdings and its competitors.
Is Nascent Pharma Holdings' EV-to-FCF too high?
Nascent Pharma Holdings' current EV-to-FCF is 73.80. The Drug Manufacturers industry median EV-to-FCF is 20.02. Nascent Pharma Holdings' value of 73.80 is 268.6% above this industry median. Overall, Nascent Pharma Holdings has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Nascent Pharma Holdings' EV-to-FCF compare to ALID and CPMD?
Nascent Pharma Holdings' EV-to-FCF of 73.80 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-FCF is 20.02. Nascent Pharma Holdings' value of 73.80 is 268.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.02, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nascent Pharma Holdings's current EV-to-FCF of 73.80 is 268.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nascent Pharma Holdings and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nascent Pharma Holdings's current EV-to-FCF is 73.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nascent Pharma Holdings stock overvalued right now?
Nascent Pharma Holdings (NASC) has a current EV-to-FCF of 73.80. The current EV-to-FCF is 73.80 and 268.6% above the Drug Manufacturers industry median of 20.02. Nascent Pharma Holdings' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nascent Pharma Holdings (NASC), the current EV-to-FCF is 73.80 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nascent Pharma Holdings Inc has acquired a Subsidiary engaged in enforcing and commercializing the patents held by Nascent. The acquired patents cover liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders, and opioid dependencies.
12GF Score
Get the complete analysis for NASC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NASC has been successfully added to your 
